Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Blood (2014) 124 (21): 1867.

https://doi.org/10.1182/blood.V124.21.1867.1867

Published: 2014

Journal Articles

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Paola Guglielmelli, Flavia Biamonte, Giada Rotunno, Valentina Artusi, Lucia Artuso, Isabella Bernardis, Elena Tenedini, Lisa Pieri, Chiara Paoli, Carmela Mannarelli, Rajmonda Fjerza, Elisa Rumi, Viktoriya Stalbovskaya, Matthew Squires, Mario Cazzola, Rossella Manfredini, Claire Harrison, Enrico Tagliafico, Alessandro M. Vannucchi

Blood (2014) 123 (14): 2157–2160.

https://doi.org/10.1182/blood-2013-11-536557

Published: 2014

Includes: Supplemental data

Journal Articles

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Paola Guglielmelli, PhD MD, Flavia Biamonte, BiSci, PhD, Lisa Pieri, MD PhD, Giada Rotunno, BiSci, Chiara Paoli, BiSci, Rajmonda Fjerza, MD, Enrico Tagliafico, MD PhD, Rossella Manfredini, PhD, Valentina Artusi, MSc, Elena Tenedini, PhD, Lucia Artuso, PhD, Isabella Bernardis, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 107.

https://doi.org/10.1182/blood.V122.21.107.107

Published: 2013

Journal Articles

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Blood (2013) 122 (21): 104.

https://doi.org/10.1182/blood.V122.21.104.104

Published: 2013

Journal Articles

Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis

Giovanni Barosi, MD, Elisa Bonetti, BS, Paolo Catarsi, PhD, Margherita Massa, PhD, Rita Campanelli, Biol.Sci, Valentina Poletto, Biol.Sci, Gianluca Viarengo, MD, Laura Villani, Biol.Sci, Gabriela Fois, Biol.Sci, Flavia Biamonte, BiSci, PhD, Giada Rotunno, BiSci, Paola Guglielmelli, PhD MD, Umberto Magrini, MD, Alessandro M Vannucchi, MD, Vittorio Rosti, MD

Blood (2013) 122 (21): 4058.

https://doi.org/10.1182/blood.V122.21.4058.4058

Published: 2013

Journal Articles

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Elena Tenedini, PhD, Isabella Bernardis, MSc, Valentina Artusi, MSc, Lucia Artuso, PhD, Enrica Roncaglia, PhD, Paola Guglielmelli, PhD MD, Lisa Pieri, PhD MD, Costanza Bogani, PhD, Flavia Biamonte, BiSci, PhD, Elisa Bianchi, PhD, Alessandro Pancrazzi, BiSci, Carmela Mannarelli, BiSci, Tiziana Fanelli, BiSci, Giada Rotunno, BiSci, Guidantonio Malagoli Tagliazucchi, MSc, Sergio Ferrari, MD, Rossella Manfredini, PhD, Alessandro M Vannucchi, MD, Enrico Tagliafico, MD PhD

Blood (2013) 122 (21): 4099.

https://doi.org/10.1182/blood.V122.21.4099.4099

Published: 2013

Journal Articles

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Blood (2012) 120 (21): 431.

https://doi.org/10.1182/blood.V120.21.431.431

Published: 2012

Journal Articles

Characterization and discovery of novel miRNAs and moRNAs in JAK2 V617F-mutated SET2 cells

Stefania Bortoluzzi, Andrea Bisognin, Marta Biasiolo, Paola Guglielmelli, Flavia Biamonte, Ruggiero Norfo, Rossella Manfredini, Alessandro M. Vannucchi

Blood (2012) 119 (13): e120–e130.

https://doi.org/10.1182/blood-2011-07-368001

Published: 2012

Includes: Supplemental data

Journal Articles

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Paola Guglielmelli, MD, PhD, Flavia Biamonte, BiSc, Johannah Score, Claire Hidalgo-Curtis, PhD, Francisco Cervantes, MD, PhD, Margherita Maffioli, MD, Tiziana Fanelli, BiSci, Thomas Ernst, MD, Nils Winkelman, MD, Amy V Jones, PhD, Katerina Zoi, MD, PhD, Andreas Reiter, MD, Andrew Duncombe, MD, Laura Villani, Biol Sci, Chiara Paoli, BiSci, Alberto Bosi, MD, Giovanni Barosi, MD, Nicholas C.P. Cross, PhD, Alessandro M. Vannucchi, MD

Blood (2011) 118 (21): 2811.

https://doi.org/10.1182/blood.V118.21.2811.2811

Published: 2011

Journal Articles

EZH2 mutational status predicts poor survival in myelofibrosis

Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi

Blood (2011) 118 (19): 5227–5234.

https://doi.org/10.1182/blood-2011-06-363424

Published: 2011

Includes: Supplemental data

Journal Articles

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Blood (2011) 118 (8): 2069–2076.

https://doi.org/10.1182/blood-2011-01-330563

Published: 2011

Includes: Supplemental data

Journal Articles

A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results

Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD, Letizia Lupo, MD, Maria Chiara Finazzi, MD, Lorenzo Tozzi, BiSc, Flavia Biamonte, BiSc, Arianna Masciulli, MD, Maria Chiara Susini, MD, Alessandro Pancrazzi, BiSc, Guido Finazzi, MD, Simona Paratore, MD, Roberto Marchioli, Alberto Bosi, Tiziano Barbui, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD

Blood (2010) 116 (21): 314.

https://doi.org/10.1182/blood.V116.21.314.314

Published: 2010

Journal Articles

Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis

Paola Guglielmelli, MD, Giovanni Barosi, MD, Alessandro Pancrazzi, PhD, Giovanni Longo, MD, Elisabetta Antonioli, MD, Lisa Pieri, MD, Flavia Biamonte, BiSci, Vanessa Ponziani, PhD, Alessandro Rambaldi, Alberto Bosi, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2008) 112 (11): 2799.

https://doi.org/10.1182/blood.V112.11.2799.2799

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Characterization and discovery of novel miRNAs and moRNAs in JAK2 V617F-mutated SET2 cells

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

EZH2 mutational status predicts poor survival in myelofibrosis

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results

Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only